VLP Therapeutics, co-founded in 2013 by Drs. Wataru Akahata, Ryuji Ueno, and Sachiko Kuno, is a biotech company with a mission to address unmet medical needs worldwide and expand the frontiers of vaccine treatment. Led by CEO Akahata VLPT is currently engaged in research and development of a cancer treatment vaccine as well as prophylactic vaccines against malaria, dengue, etc. using VLPT's proprietary platform technologies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/28/21 | $21,000,000 | Series A-1 |
Miyako Capital MUFG Bank Nobelpharma Co. Robert G. Hisaoka SK Impact Fund Sojitz Corporation | undisclosed |
